### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

# **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	The commercial reagents including provide	
name, catalogue number and RRID, if available.	supplier name and catalogue number were	
	provided in Method/Reagents, Pages 4-5, Line	
	114-123	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
<b>Cell lines:</b> Provide species information, strain.	The cell lines information was provided in	
Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID	Method/cell culture", Pages 5, Line 124-141	
<b>Primary cultures:</b> Provide species, strain, sex of		√
origin, genetic modification status.		Not included

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		√
genetic modification status. Provide accession		Not
number in repository <b>OR</b> supplier name, catalog		included
number, clone number, <b>OR</b> RRID		
Animal observed in or captured from the		<b>√</b>
field: Provide species, sex and age where		Not
possible		included
Model organisms: Provide Accession number		<b>√</b>
in repository (where relevant) <b>OR</b> RRID		

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
<b>Plants:</b> provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		√ Not included
<b>Microbes:</b> provide species and strain, unique accession number if available, and source		√ Not included

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or		√
equivalent committee(s), provide reference number		Not
for approval.		included
Provide statement confirming informed consent		√
obtained from study participants.		Not
		included
Report on age and sex for all study participants.		√
		Not
		included

## **Design**

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration		√
number <b>OR</b> cite DOI in manuscript.		Not included

Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	The tubulin polymerization assay was performed according to our previously reported methods (DOI: 10.1016/j.bcp.2015.07.008) and indicated in "In vitro tubulin polymerization assay", Line 140-153"  Colchicine competitive binding assay", Line 155-166. DOI: 10.1021/acs.jmedchem.1c01775.	

Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been		
done, or if they were not carried out.		
Sample size determination		√
		not carried out
Randomisation		√
		not carried out
Blinding		$\checkmark$
		not carried out
Inclusion/exclusion criteria		√
		not carried out

Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory	The number of times the experiment replicated were indicated in Figure Legends as "All experiments were repeated for 3 independent times"	
Define whether data describe technical or biological replicates	Yes, we have described that the data were images were obtained from 3 independent repeated experiments, that were biological replicates.	

Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		√ not carried out
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		√ not carried out
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		√ not carried out

Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern,		$\checkmark$
state the authority granting approval and reference		not carried out
number for the regulatory approval		

## **Analysis**

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is		√
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a	
Describe statistical tests used and justify choice of		√	
tests.			Ì

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,		√
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession		√
number in repository or DOI or URL.		
If publicly available data are reused, provide		√
accession number in repository or DOI or URL, where		
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.		√
If code is publicly available, provide accession		~
number in repository, or DOI or URL.		

## Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: <a href="https://dx.doi.org/10.21037/jgo-23-842">https://dx.doi.org/10.21037/jgo-23-842</a>